Please use this identifier to cite or link to this item:
http://hdl.handle.net/10553/54610
Title: | Síndrome meníngeo y síndrome de Guillain-Barrè en un paciente con artritis reumatoide tratado con adalimumab | Other Titles: | Meningeal and Guillain-Barrè syndrome in a patient with rheumatoid arthritis receiving adalimumab therapy | Authors: | Martín Santana, Idaira Ruano Hernández, Arminda Hernández Beriain, José ángel Hervás García, Miguel López Méndez, P. Reyes Yáñez, María del Pino |
UNESCO Clasification: | 320509 Reumatología | Keywords: | Factor de necrosis tumoral alfa Anticuerpos monoclonales Artritis reumatoide Síndrome meníngeo Síndrome de Guillain-Barrè, et al |
Issue Date: | 2011 | Journal: | Reumatologia Clinica | Abstract: | Adalimumab es un anticuerpo monoclonal recombinante humano que bloquea el efecto del factor de necrosis tumoral alfa. Actualmente se emplea como tratamiento para la artritis reumatoide, siendo la desmielinización un potencial efecto adverso. Nuestro caso trata de un varón de 31 años con artritis reumatoide seropositiva que presentó un cuadro diarreico después de la segunda dosis de adalimumab. Tras tratamiento con ciprofloxacino el paciente desarrolló un síndrome de Guillain-Barrè confirmado por electromiografía. El estudio del líquido cefalorraquídeo sugirió un síndrome meníngeo o una posible meningitis bacteriana decapitada. El tratamiento con adalimumab puede asociarse con el desarrollo de enfermedades desmielinizantes e infecciosas y afectar simultáneamente al sistema nervioso central y al periférico. Adalimumab is a recombinant human monoclonal antibody that blocks the effects of tumor necrosis factor-alpha, and is presently used for treatment of rheumatoid arthritis, with demyelination being a potential adverse effect. A 31 year-old male with seropositive rheumatoid arthritis presented with diarrhea after the second injection of adalimumab. He was treated with ciprofloxacin. In a few days he developed a Guillain-Barrè syndrome confirmed by electromyography, and his cerebrospinal fluid was compatible with meningeal syndrome or partially treated bacterial meningitis. Adalimumab may be associated with the development of demyelination and infectious diseases. Moreover, both the central nervous system and the peripheral nervous system can be affected. |
URI: | http://hdl.handle.net/10553/54610 | ISSN: | 1699-258X | DOI: | 10.1016/j.reuma.2011.01.009 | Source: | Reumatología clínica [ISSN 1699-258X], v. 7 (6), p. 401-403 | URL: | http://dialnet.unirioja.es/servlet/articulo?codigo=3769594 |
Appears in Collections: | Artículos |
SCOPUSTM
Citations
7
checked on Aug 25, 2024
WEB OF SCIENCETM
Citations
5
checked on Aug 25, 2024
Page view(s)
145
checked on Feb 26, 2023
Google ScholarTM
Check
Altmetric
Share
Export metadata
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.